ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KPTI vs CTXR // ALTMAN Z-SCORE & DEBT/EQUITY

Karyopharm Therapeutics Inc. (NASDAQ) VS. Citius Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: KPTI 2 — CTXR 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KPTI VS. CTXR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KPTI CTXR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 0.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 1/9 +1.00 KPTI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.3 52.5 -8.20 CTXR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $15.0M $14.4M $654.7K KPTI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KPTI REV CTXR REV KPTI GROSS % CTXR GROSS % KPTI FCF CTXR FCF
FY 2025 $146.1M $107.9M — — -$75.4M -$26.6M
FY 2024 $145.2M $117.6M — — -$127.6M -$28.2M
FY 2023 $146.0M $102.8M — — -$92.7M -$29.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KPTI // BETA —
CTXR // BETA —